T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Detalles Bibliográficos
Autores principales: Moskowitz, Alison J., Shah, Gunjan, Schöder, Heiko, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Sohail, Samia, Santarosa, Alayna, Capadona, Charisse, Munayirji, Brittney, Kumar, Anita, Lahoud, Oscar, Batlevi, Connie, Hamlin, Paul, Straus, David J., Owens, Colette, Caron, Philip, Intlekofer, Andrew, Hamilton, Audrey, Horwitz, Steven, Falchi, Lorenzo, Johnson, William, Palomba, Lia, Noy, Ariela, Matasar, Matthew, Pongas, Georgios, Salles, Gilles, Vardhana, Santosha, Sanin, Beatriz Wills, Yahalom, Joachim, Dogan, Ahmet, Zelenetz, Andrew, Moskowitz, Craig H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Relapsed/Refractory
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621500/
http://dx.doi.org/10.1097/01.HS9.0000890964.54059.2c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621500/
http://dx.doi.org/10.1097/01.HS9.0000890964.54059.2c

Ejemplares similares